Publication Date:
2013-11-30
Description:
18F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib Blood Cancer Journal 3, e165 (November 2013). doi:10.1038/bcj.2013.61 Authors: K Duncan, T R Rosean, V S Tompkins, A Olivier, R Sompallae, F Zhan, G Tricot, M R Acevedo, L L B Ponto, S A Walsh, L T Tygrett, A J Berger, T Waldschmidt, H C Morse, J J Sunderland & S Janz
Keywords:
GEMM (genetically engineered mouse model) of human cancerpreclinical cancer drug testingplasma cell neoplasia
Electronic ISSN:
2044-5385
Topics:
Medicine
Permalink